The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its next chapter.
Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk
— a once-daily drug that shares the same brand name as its popular injection Wegovy. A GLP-1 pill from the company’s chief rival Eli Lilly
isn’t far behind, with a U.S. approval expected within months.
For some people, pills may serve as a more convenient — and potentially cheaper — alternative to today’s blockbuster injections. The cash prices of Novo Nordisk’s Wegovy pill range from $149 to $299 per month, depending on the dose, which is slightly less than the newly lowered cash prices of injections.
